Before the administration of malaria treatment, WHO recommended prompt parasite-based diagnosis in all patients suspected of malaria. Rapid diagnostic tests (RDTs) can significantly improve the quality of management of malaria infections, especially in remote areas that lack high quality microscopy services. RDTs allow for the diagnosis of malaria at the community level and are relatively simple to perform and interpret, provide fast results, and only require limited training.5 RDT use has been significantly expanded in recent years around the world. According to manufacturers surveyed for the World Malaria Report 2021, 3.1 billion malaria RDTs were sold in 2010–2020, with nearly 81% of these sales being to sub- Saharan Africa. Additionally, 2.2 billion RDTs were distributed through national malaria programmes, of which 88% were in sub-Saharan Africa.5
The availability of high-quality, inexpensive RDTs has made it possible to significantly improve and expand diagnostic testing across all levels of the health system, from district hospitals to community-based programs.5
Our malaria rapid tests are some of the most widely used malaria RDTs in the world. Based on the outstanding quality performance, Bioline Malaria Ag P.f. was the first test in the world to complete the WHO prequalification process, the BinaxNOW® Malaria test was the first FDA-cleared Malaria RDT and the NxTek™Eliminate Malaria Pf test is able to detect people with low parasitemia.